NSCLC

Non-small-cell lung carcinoma is any type of epithelial lung cancer other than small-cell lung carcinoma. NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

Read more in the app

Novel immunotherapy strategy shows promising long-term survival in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors - EurekAlert!

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors - EurekAlert!

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy - EurekAlert!

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study - EurekAlert!

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations - EurekAlert!

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds - EurekAlert!

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients - EurekAlert!

NKAPL: a promising biomarker for NSCLC diagnosis and treatment - EurekAlert!

HER2-mutated NSCLC in Brazil shows diverse genetic patterns and treatment gaps - EurekAlert!

Immune checkpoint inhibitors significantly increase myocarditis risk in NSCLC patients - EurekAlert!

Long-term benefit of SABR for operable early-stage NSCLC shown in new study

Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC

Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC

Radiation Oncology trials using PET with FDG uptake among NSCLC patients

Sotorasib provides durable clinical benefit for patients with NSCLC and KRAS mutations